9 March 2015

Supporting life science innovation in Oxfordshire and beyond

Oxford PharmaGenesis has recently joined OBN, the UK membership organization for innovative life science R&D companies in the golden triangle of Oxford, Cambridge and London – and beyond. Chris Winchester, Managing Director of Oxford PharmaGenesis, comments, “We are proud to be part of a support network for emerging life-science companies and offer our communications expertise.”

Oxford PharmaGenesis has recently joined OBN, the UK membership organization for innovative life science R&D companies in the golden triangle of Oxford, Cambridge and London – and beyond. Chris Winchester, Managing Director of Oxford PharmaGenesis, comments, “We are proud to be part of a support network for emerging life-science companies and offer our communications expertise.” Continue reading

4 March 2015

Oxford PharmaGenesis at the forefront of good publication practice: report from TIPPA's 14th Annual Meeting

Real-world evidence (RWE) study publications and clinical trial data disclosure were two major topics of discussion at the 14th Annual Meeting of The International Publication Planning Association (TIPPA), with both keynote sessions being led by Oxford PharmaGenesis. The meeting, held in San Diego on 9–10 February 2015, was attended by an approximately even mix of pharmaceutical company publications managers and communications agencies, with several major publishing groups also exhibiting. Continue reading

27 February 2015

#1in10 Campaign for Rare Disease Day

Did you know that 1 in 10 people in the USA are living with a rare disease? To put it in perspective, that’s approximately the same as the number of people who are left-handed!

Rare diseases don’t discriminate – they affect all races and religions, rich and poor, young and old. They are often chronic and life-threatening, 80% are genetic and about 50% affect children. A third of children who have a rare disease will not live to celebrate their fifth birthday. Of the 7000 known rare diseases, fewer than 400 have FDA-approved treatments and most patients face the same additional challenges: lack of information, limited access to specialist care and social isolation. Continue reading

27 February 2015

Our Chairman rows for charity

Our company Chairman and founder, Graham Shelton, is taking up a different challenge next month by taking part in The Rotary Club of Oxford North Charity Rowathon. This will involve rowing the distance of the Oxford and Cambridge Boat Race for the charity SSNAP, which supports sick and premature babies and their families. Continue reading

12 February 2015

Probiotics consensus tops rankings of leading journal

Digestion conceptA consensus article co-authored by researchers from the European Society for Primary Care Gastroenterology and Oxford PharmaGenesis is in the top 10 most accessed papers in a leading gastroenterology journal. The systematic-review-based consensus article breaks new ground by summarizing complex information for clinicians in primary care regarding the use of probiotics in the treatment of patients with lower gastrointestinal symptoms. The article, which first appeared online in 2013, was downloaded nearly 5000 times in 2014, placing it in the top 10 recently published papers in Alimentary Pharmacology & Therapeutics by electronic downloads. It was also placed in the top 10 most cited of all articles published in the journal in 2013–14. Continue reading

6 February 2015

Wear it. Beat it … Eat it!

[vc_row][vc_column width=”1/1″][vc_column_text]HEARTMany of us at Oxford PharmaGenesis have been busy baking this week in preparation for a cake sale in aid of the British Heart Foundation’s ‘WEAR IT. BEAT IT.’ initiative. Those who fancied a slice of the action have been putting on their aprons and picking up their wooden spoons to whip up a storm.

Continue reading

1 25 26 27 28 29 31